A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy

Mark Haas(Cedars-Sinai Medical Center), Jacobien C. Verhave(Radboud University Nijmegen), Zhi-Hong Liu(Nanjing University), Charles E. Alpers(University of Washington), Jonathan Barratt(University of Leicester), Jan U. Becker(University Hospital Cologne), Daniel C. Cattran(University Health Network), H. Terence Cook(Centre for Inflammation Research), Rosanna Coppo(Fondazione Ricerca Molinette), John Feehally(University of Leicester), Antonello Pani(Azienda Ospedaliera G. Brotzu), Agnieszka Perkowska‐Ptasińska(Medical University of Warsaw), Ian S.D. Roberts(Oxford University Hospitals NHS Trust), Maria Fernanda Soares, Hernán Trimarchi(Hospital Británico de Buenos Aires), Suxia Wang(Pathological Society), Yukio Yuzawa(Fujita Health University), Hong Zhang(Peking University), Stéphan Troyanov(Hôpital du Sacré-Cœur de Montréal), Ritsuko Katafuchi(Fukuoka Higashi Medical Center)
Journal of the American Society of Nephrology
September 9, 2016
Cited by 307Open Access
Full Text

Abstract

The Oxford Classification of IgA nephropathy does not account for glomerular crescents. However, studies that reported no independent predictive role of crescents on renal outcomes excluded individuals with severe renal insufficiency. In a large IgA nephropathy cohort pooled from four retrospective studies, we addressed crescents as a predictor of renal outcomes and determined whether the fraction of crescent-containing glomeruli associates with survival from either a ≥50% decline in eGFR or ESRD (combined event) adjusting for covariates used in the original Oxford study. The 3096 subjects studied had an initial mean±SD eGFR of 78±29 ml/min per 1.73 m 2 and median (interquartile range) proteinuria of 1.2 (0.7–2.3) g/d, and 36% of subjects had cellular or fibrocellular crescents. Overall, crescents predicted a higher risk of a combined event, although this remained significant only in patients not receiving immunosuppression. Having crescents in at least one sixth or one fourth of glomeruli associated with a hazard ratio (95% confidence interval) for a combined event of 1.63 (1.10 to 2.43) or 2.29 (1.35 to 3.91), respectively, in all individuals. Furthermore, having crescents in at least one fourth of glomeruli independently associated with a combined event in patients receiving and not receiving immunosuppression. We propose adding the following crescent scores to the Oxford Classification: C0 (no crescents); C1 (crescents in less than one fourth of glomeruli), identifying patients at increased risk of poor outcome without immunosuppression; and C2 (crescents in over one fourth of glomeruli), identifying patients at even greater risk of progression, even with immunosuppression.


Related Papers

No related papers found

Powered by citation graph analysis